Recombinant Human EphA4 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human EphA4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  When Recombinant Human EphA4 Fc Chimera is coated at 2 μg/mL (100 μL/well), the concentration of biotinylayed Recombinant Human Ephrin-A5 Fc Chimera (Catalog # 374-EA) that produces 50% of the optimal binding response is found to be approximately 5-25 ng/mL.

• Source: Mouse myeloma cell line, NS0-derived human EphA4 protein
  

  Human EphA4 (Met1 - Thr547) Accession # NP_004429.1	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: NP_004429.1
• N-terminal Sequence: Val20
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: EPHA4
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 85 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 93-98 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human EphA4 Fc Chimera Protein, CF

• Cek8
• EC 2.7.10
• EC 2.7.10.1
• EK8
• EPH receptor A4
• EphA4
• EPH-like kinase 8
• ephrin type-A receptor 4
• Hek8
• receptor protein-tyrosine kinase HEK8
• SEK
• Sek1
• TYRO1 protein tyrosine kinase
• Tyro1
• Tyrosine-protein kinase receptor SEK
• Tyrosine-protein kinase TYRO1

Background

EphA4, also known as Hek8, Tyro1, and Sek, is a 120 ‑ 130 kDa glycosylated member of the Eph family of transmembrane receptor tyrosine kinases (1, 2). The A and B classes of Eph proteins are distinguished by Ephrin ligand binding preference but have a common structural organization. EphA4 is unusual in its ability to be activated by both Ephrin-A and -B molecules, although its interactions with Ephrin-B2 and -B3 are weaker than with Ephrin-A ligands (3, 4). Eph-Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression. The 528 amino acid (aa) extracellular domain (ECD) of human EphA4 contains an N-terminal Ephrin binding region, a cysteine-rich region, and two fibronectin type III domains (FnIII). The 417 aa cytoplasmic domain contains the tyrosine kinase domain and a sterile alpha motif (SAM) (5). Within the ECD, human EphA4 shares 98% aa sequence identity with mouse and rat EphA4. EphA4 is activated by interactions with Ephrin ligands, triggering a repulsive effect on neurite outgrowth (6, 7). This function is important for the accurate guidance and pathfinding of axons in the spiral ganglion of the cochlea, the anterior commissure, and the corticospinal tract (6 ‑ 8). Neuronal EphA4 interactions with astrocyte‑expressed Ephrins also plays a critical role in long term potentiation by regulating hippocampal neuron dendrite arborization, spine maturation, and function (9 - 11). The up‑regulation of EphA4 in gastric carcinoma is negatively correlated with patient survival (12). In glioma, EphA4 associates with FGF R1, and this enhances FGF basic-induced tumor cell migration (13). EphA4 is also involved in morphogenesis of the thymic epithelium and T cell development (14).

1. Pasquale, E.B. (2005) Nat. Rev. Mol. Cell Biol. 6:462.
2. Merlos-Suarez, A. and E. Batlle (2008) Curr. Opin. Cell Biol. 20:194.
3. Gale, N.W. et al. (1996) Neuron 17:9.
4. Qin, H. et al. (2010) J. Biol. Chem. 285:644.
5. Fox, G.M. et al. (1995) Oncogene 10:897.
6. Brors, D. et al. (2003) J. Comp. Neurol. 462:90.
7. Ho, S.K.Y. et al. (2009) Neuroscience 160:784.
8. Canty, A.J. et al. (2006) Proc. Natl. Acad. Sci. 103:15629.
9. Murai, K.K. et al. (2003) Nat. Neurosci. 6:153.
10. Filosa, A. et al. (2009) Nat. Neurosci. 12:1285.
11. Fu, A.K.Y. et al. (2011) Nat. Neurosci. 14:181.
12. Oki, M. et al. (2008) World J. Gastroenterol. 14:5650.
13. Fukai, J. et al. (2008) Mol. Cancer Ther. 7:2768.
14. Munoz, J.J. et al. (2006) J. Immunol. 177:804.

Publications for EphA4 (6827-A4)(3)

Publications using 6827-A4

• JH Cha, LC Chan, YN Wang, YY Chu, CH Wang, HH Lee, W Xia, WC Shyu, SP Liu, J Yao, CW Chang, FR Cheng, J Liu, SO Lim, JL Hsu, WH Yang, GN Hortobagyi, C Lin, L Yang, D Yu, LB Jeng, MC Hung Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer The Journal of Biological Chemistry, 2022-03-10;0(0):101817. 2022-03-10 [PMID: 35278434] (ELISA Capture, N/A)
• L Teo, AG Boghdadi, J Homman-Lud, IC Mundinano, WC Kwan, JA Bourne Replicating infant-specific reactive astrocyte functions in the injured adult brain Progress in neurobiology, 2021-06-17;0(0):102108. 2021-06-17 [PMID: 34147584] (Bioassay, Human)
• L Schoonaert, L Rué, B Roucourt, M Timmers, S Little, L Chávez-Gut, M Dewilde, P Joyce, A Curnock, P Weber, J Haustraete, G Hassanzade, B De Stroope, L Van Den Bo, P Van Damme, R Lemmens, W Robberecht Identification and characterization of Nanobodies targeting the EphA4 receptor J. Biol. Chem., 2017-05-19;292(27):11452-11465. 2017-05-19 [PMID: 28526745] (Bioassay, Mouse)

Bioinformatics

• Gene Symbol: EPHA4
• Uniprot:
  • NP_004429.1()